Skip to content. | Skip to navigation

Personal tools



logo Inserm      logo cnrslogo ENSL       logo ucb1

You are here: Home / Teams / Baize S - UBIVE / Publications


1.            Pannetier, D., et al., Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever. PLoS Negl Trop Dis, 2014. 8(1): p. e2637.

2.            Reynard, S., et al., Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response. J Virol, 2014. 88(23): p. 13923-7.

3.            Russier, M., et al., The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses. J Virol, 2014. 88(23): p. 13811-20.

4.            Matheron, S., et al., Ebola: should we consider influenza vaccination? Lancet, 2014. 384(9959): p. 2023-4.

5.            Kuhn, J.H., et al., Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses, 2014. 6(11): p. 4760-99.

6.            Baize, S., et al., Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med, 2014. 371(15): p. 1418-25.

7.            Salvetti, A. and S. Baize, [Viral zoonoses and emergence: research is just starting]. Med Sci (Paris), 2015. 31(12): p. 1055-6.

8.            Baize, S., Ebola virus in West Africa: new conquered territories and new risks-or how I learned to stop worrying and (not) love Ebola virus. Curr Opin Virol, 2015. 10: p. 70-6.

9.            Reusken, C., et al., Identification of essential outstanding questions for an adequate European laboratory response to Ebolavirus Zaire West Africa 2014. J Clin Virol, 2015. 62: p. 124-34.

10.          Sagui, E., et al., Severe Ebola Virus Infection With Encephalopathy: Evidence for Direct Virus Involvement. Clin Infect Dis, 2015. 61(10): p. 1627-8.

11.          Baize, S., Towards deep insight into Ebola virus disease. Lancet Infect Dis, 2015. 15(9): p. 991-992.

12.          Sissoko, D., et al., Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med, 2016. 13(4): p. e1002009.

13.          van Griensven, J., et al., Efficacy of Convalescent Plasma in Relation to Dose of Ebola Virus Antibodies. N Engl J Med, 2016. 375(23): p. 2307-2309.

14.          van Griensven, J., et al., Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med, 2016. 374(1): p. 33-42.

15.          Nocquet, J.M., et al., Present-day uplift of the western Alps. Sci Rep, 2016. 6: p. 28404.

16.          Sissoko, D., et al., Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med, 2016. 13(3): p. e1001967.

17.          Sow, M.S., et al., New Evidence of Long-lasting Persistence of Ebola Virus Genetic Material in Semen of Survivors. J Infect Dis, 2016. 214(10): p. 1475-1476.

18.          Mailles, A., et al., Strengthened Ebola surveillance in France during a major outbreak in West Africa: March 2014-January 2016. Epidemiol Infect, 2017. 145(16): p. 3455-3467.

19.          Nguyen, T.H., et al., Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis, 2017. 11(2): p. e0005389.

20.          Subtil, F., et al., Dynamics of Ebola RNA Persistence in Semen: A Report From the Postebogui Cohort in Guinea. Clin Infect Dis, 2017. 64(12): p. 1788-1790.

21.          Vernet, M.A., et al., Clinical, virological, and biological parameters associated with outcomes of Ebola virus infection in Macenta, Guinea. JCI Insight, 2017. 2(6): p. e88864.

22.          Etard, J.F., et al., Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis, 2017. 17(5): p. 545-552.

23.          Tartour, K., et al., Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. PLoS Pathog, 2017. 13(9): p. e1006610.

24.          Carnec, X., et al., A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J Virol, 2018. 92(12).

25.          Schaeffer, J., et al., Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells. PLoS Pathog, 2018. 14(11): p. e1007430.

26.          Madelain, V., et al., Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. Nat Commun, 2018. 9(1): p. 4013.

27.          Baize, S., [Lassa virus and myeloid dendritic cells: a privileged tropism for the suppression of the T lymphocyte response]. Med Sci (Paris), 2019. 35(8-9): p. 619-621.

28.          Keita, A.K., et al., A 40-Month Follow-Up of Ebola Virus Disease Survivors in Guinea (PostEbogui) Reveals Long-Term Detection of Ebola Viral Ribonucleic Acid in Semen and Breast Milk. Open Forum Infect Dis, 2019. 6(12): p. ofz482.

29.          Baillet, N., et al., E3 Ligase ITCH Interacts with the Z Matrix Protein of Lassa and Mopeia Viruses and Is Required for the Release of Infectious Particles. Viruses, 2019. 12(1).

30.          Reynard, S., et al., Immune parameters and outcomes during Ebola virus disease. JCI Insight, 2019. 4(1).

31.          Schaeffer, J., et al., Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus. Viruses, 2019. 11(3).

32.          Baillet, N., et al., Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses. Viruses, 2019. 11(3).

33.          Mateo, M., et al., Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci Transl Med, 2019. 11(512).

34.          Mateo, M., et al., Fatal Case of Lassa Fever, Bangolo District, Cote d'Ivoire, 2015. Emerg Infect Dis, 2019. 25(9): p. 1753-1756.

35.          Yadouleton, A., et al., Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus. Emerg Microbes Infect, 2020. 9(1): p. 1761-1770.

36.          Cohen-Dvashi, H., et al., Rational design of universal immunotherapy for TfR1-tropic arenaviruses. Nat Commun, 2020. 11(1): p. 67.

37.          Madelain, V., et al., Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials. CPT Pharmacometrics Syst Pharmacol, 2020. 9(5): p. 258-271.

38.          Baize, S., [A single shot vaccine against Lassa fever]. Med Sci (Paris), 2020. 36(10): p. 844-847.

39.          Baillet, N., et al., Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques. Commun Biol, 2021. 4(1): p. 27.

40.          Reynard, S., et al., Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates. PLoS Negl Trop Dis, 2021. 15(3): p. e0009300.